Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2017 Jan 31

PMID 28135086

Citations 25

Authors

Sandeep Sundriyal

Sebastien Moniot

Zimam Mahmud

Shang Yao

Paolo Di Fruscia

Christopher R Reynolds

David T Dexter

Michael J E Sternberg

Eric W-F Lam

Clemens Steegborn

Matthew J Fuchter

Affiliations

Soon will be listed here.

Abstract

Sirtuins (SIRTs) are NAD-dependent deacylases, known to be involved in a variety of pathophysiological processes and thus remain promising therapeutic targets for further validation. Previously, we reported a novel thienopyrimidinone SIRT2 inhibitor with good potency and excellent selectivity for SIRT2. Herein, we report an extensive SAR study of this chemical series and identify the key pharmacophoric elements and physiochemical properties that underpin the excellent activity observed. New analogues have been identified with submicromolar SIRT2 inhibtory activity and good to excellent SIRT2 subtype-selectivity. Importantly, we report a cocrystal structure of one of our compounds (29c) bound to SIRT2. This reveals our series to induce the formation of a previously reported selectivity pocket but to bind in an inverted fashion to what might be intuitively expected. We believe these findings will contribute significantly to an understanding of the mechanism of action of SIRT2 inhibitors and to the identification of refined, second generation inhibitors.

Citing Articles

Neuroprotective thiazole sulfonamides against 6-OHDA-induced Parkinsonian model: biological and pharmacokinetic assessments.

Ruankham W, Pingaew R, Prachayasittikul V, Worachartcheewan A, Sathuphong S, Apiraksattayakul S RSC Adv. 2025; 15(6):4281-4295.

PMID: 39931414 PMC: 11809491. DOI: 10.1039/d4ra04941a.

Multicomponent reactions (MCRs) yielding medicinally relevant rings: a recent update and chemical space analysis of the scaffolds.

Tandi M, Sharma V, Gopal B, Sundriyal S RSC Adv. 2025; 15(2):1447-1489.

PMID: 39822567 PMC: 11736855. DOI: 10.1039/d4ra06681b.

Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity.

Shenk T, Kulp Iii J, Chiang L Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458938 PMC: 11510315. DOI: 10.3390/ph17101298.

Discovery of Novel Thiazole-Based SIRT2 Inhibitors as Anticancer Agents: Molecular Modeling, Chemical Synthesis and Biological Assays.

Piacente F, Guccione G, Scarano N, Lunaccio D, Miro C, Abbotto E Int J Mol Sci. 2024; 25(20).

PMID: 39456864 PMC: 11508362. DOI: 10.3390/ijms252011084.

Computational Design and Optimization of Peptide Inhibitors for SIRT2.

Alkhatabi H, Naemi F, Alsolami R, Alatyb H Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338285 PMC: 11435109. DOI: 10.3390/ph17091120.

References

Mahajan S, Scian M, Sripathy S, Posakony J, Lao U, Loe T . Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem. 2014; 57(8):3283-94. PMC: 4002067. DOI: 10.1021/jm4018064. View

Gong C, Yao S, Gomes A, Man E, Lee H, Gong G . BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer. Oncogenesis. 2016; 5:e214. PMC: 4848836. DOI: 10.1038/oncsis.2016.23. View

Galli M, Van Gool F, Leo O . Sirtuins and inflammation: Friends or foes?. Biochem Pharmacol. 2010; 81(5):569-76. DOI: 10.1016/j.bcp.2010.12.010. View

Karplus P, Diederichs K . Linking crystallographic model and data quality. Science. 2012; 336(6084):1030-3. PMC: 3457925. DOI: 10.1126/science.1218231. View

Grozinger C, Chao E, Blackwell H, Moazed D, Schreiber S . Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001; 276(42):38837-43. DOI: 10.1074/jbc.M106779200. View

Smith B, Denu J . Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. J Biol Chem. 2007; 282(51):37256-65. DOI: 10.1074/jbc.M707878200. View

Rumpf T, Schiedel M, Karaman B, Roessler C, North B, Lehotzky A . Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat Commun. 2015; 6:6263. PMC: 4339887. DOI: 10.1038/ncomms7263. View

Chakrabarty S, Ramapanicker R, Mishra R, Chandrasekaran S, Balaram H . Development and characterization of lysine based tripeptide analogues as inhibitors of Sir2 activity. Bioorg Med Chem. 2009; 17(23):8060-72. DOI: 10.1016/j.bmc.2009.10.003. View

Cui H, Kamal Z, Ai T, Xu Y, More S, Wilson D . Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. J Med Chem. 2014; 57(20):8340-57. DOI: 10.1021/jm500777s. View

10.

Zhao D, Zou S, Liu Y, Zhou X, Mo Y, Wang P . Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 2013; 23(4):464-76. PMC: 3885615. DOI: 10.1016/j.ccr.2013.02.005. View

11.

Schutkowski M, Fischer F, Roessler C, Steegborn C . New assays and approaches for discovery and design of Sirtuin modulators. Expert Opin Drug Discov. 2014; 9(2):183-99. DOI: 10.1517/17460441.2014.875526. View

12.

Lee A, Jung Y, Kim D, Nguyen-Thanh T, Kang K, Lee S . SIRT2 ameliorates lipopolysaccharide-induced inflammation in macrophages. Biochem Biophys Res Commun. 2014; 450(4):1363-9. DOI: 10.1016/j.bbrc.2014.06.135. View

13.

Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park S . SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 2008; 135(5):907-18. PMC: 2853975. DOI: 10.1016/j.cell.2008.10.025. View

14.

Suzuki T, Asaba T, Imai E, Tsumoto H, Nakagawa H, Miyata N . Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine. Bioorg Med Chem Lett. 2009; 19(19):5670-2. DOI: 10.1016/j.bmcl.2009.08.028. View

15.

Wang R, Sengupta K, Li C, Kim H, Cao L, Xiao C . Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008; 14(4):312-23. PMC: 2643030. DOI: 10.1016/j.ccr.2008.09.001. View

16.

Turkmen K, Karagoz A, Kucuk A . Sirtuins as novel players in the pathogenesis of diabetes mellitus. World J Diabetes. 2014; 5(6):894-900. PMC: 4265877. DOI: 10.4239/wjd.v5.i6.894. View

17.

Du J, Zhou Y, Su X, Yu J, Khan S, Jiang H . Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011; 334(6057):806-9. PMC: 3217313. DOI: 10.1126/science.1207861. View

18.

Avalos J, Bever K, Wolberger C . Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell. 2005; 17(6):855-68. DOI: 10.1016/j.molcel.2005.02.022. View

19.

Rice C, Sun M, Kemp K, Gray E, Wilkins A, Scolding N . Mitochondrial sirtuins--a new therapeutic target for repair and protection in multiple sclerosis. Eur J Neurosci. 2012; 35(12):1887-93. DOI: 10.1111/j.1460-9568.2012.08150.x. View

20.

Chakraborty C, George Priya Doss C . Sirtuins family--recent development as a drug target for aging, metabolism, and age related diseases. Curr Drug Targets. 2013; 14(6):666-75. DOI: 10.2174/1389450111314060008. View